|

Metformin in Safety and Efficacy in Gouty Patients

RECRUITINGPhase 2Sponsored by Mostafa Bahaa
Actively Recruiting
PhasePhase 2
SponsorMostafa Bahaa
Started2025-04-20
Est. completion2026-11-20
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06924658

Summary

The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Eligibility

Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.

Exclusion Criteria:

* Systemic disorders such as cardiovascular, neurological, coronary artery disease.
* Hypertension, hyperlipidemia, diabetes mellitus, active infections.
* Other inflammatory or autoimmune diseases.
* Patients on biologics,
* Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.

Conditions2

ArthritisGout

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.